ArticleJournal of ovarian research2025
Immunotherapy in young adults with mature cystic ovarian Teratoma-Derived squamous cell carcinoma: a case series.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMature cystic teratomas (MCTs), also known as dermoid cysts, are common benign germ cell tumors. These predominantly benign tumors can become malignant, particularly in postmenopausal women; the overall transformation rate of MCTs is 1-2%, accounting for approximately 80% squamous cell carcinoma of cases. Malignant transformation remains exceptionally rare in young adults. CASE PRESENTATION: Herein, we report two cases of squamous cell carcinoma arising from MCTs in a 25-year-old patient, staged FIGO 2018 IIIA1 and IC2 according to the International Federation of Gynecology and Obstetrics (FIGO) 2018 classification. The results of histopathological examination confirmed squamous cell carcinoma arising from the teratomas. Immunohistochemical staining revealed programmed death-ligand 1 expression. Both patients underwent fertility-sparing surgeries and subsequently received adjuvant chemotherapy in combination with programmed death receptor 1 (PD-1) inhibitor immunotherapy. A complete clinical response was ultimately achieved. Patients 1 and 2 were monitored for 29 and 20 months after operation, respectively. A complete response was maintained in Patients1 and 2 for 14 and 16 months, respectively, as of the last follow-up.
conclusionSquamous cell carcinoma arising from MCTs is exceedingly rare in young adults and exhibits nonspecific clinical manifestations and imaging characteristics, hindering preoperative diagnosis. These tumors display highly aggressive biological behavior and are typically associated with a poor prognosis and a high postoperative recurrence rate. Immunotherapy intervention at diverse different time points for patients at different stages can increase their survival period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.